作者： 林京 来源： Tech星球 医美巨头华熙生物，依旧在经历阵痛期。 以下文章来源于Tech星球 ，作者林京 ------------------------------- Tech星球 . Tech星球，聚焦互联网前沿科技和新商业。 随着玻尿酸市场红利消退，华熙生物的业绩还在不断承压。 今年前三季度，华熙生物营业收入同比 减少18.36%至31.63亿元，归母净利润较上年同期下滑30.29%至2.52亿元。 12月5日，华熙生物股价更是以45.57元收盘， 跌破47.79元的发行价，总市值仅剩220亿， 相较 昔日最高峰1400亿市值，已经蒸发千亿。 此外，据凤凰网科技等报道，华熙生物发布了一封"同舟共济、共克时艰"的全员邮件，称受市场环 境波动影响，公司经营业绩面临较大压力。为确保长期稳健发展，公司需对现有福利政策进行合规 性优化调整。 其中，白2025年12月起，华熙生物及各分子公司的住房公积金缴存比例统一调整为5%。 自2025 年12月起，原设定的节日礼金将暂停发放。后续公司将通过员工关怀活动、弹性福利平台等方式， 持续关注大家的工作与生活需求。 截至发稿，华熙生物对此邮件内容暂无公开回应。 尽 ...

Group 1 - The Shanghai Stock Exchange and China Securities Index Co., Ltd. announced the periodic adjustment results for indices such as SSE 50, SSE 180, SSE 380, and Sci-Tech 50, effective after market close on December 12, 2025, with changes including 4 samples for SSE 50, 7 for SSE 180, 38 for SSE 380, and 2 for Sci-Tech 50 [1] - Huaxi Biological was removed from the Sci-Tech 50 index adjustment list [2] - The adjustment of Huaxi Biological has been anticipated, as the company reported a significant decline in its skin science innovation transformation business, with no brands achieving over 1 billion in revenue last year [3][4] Group 2 - In the 2024 annual report, Huaxi Biological renamed its "Personal Health Consumer Products Business Line" to "Skin Science Innovation Transformation Business Line," which generated revenue of 2.569 billion yuan, a year-on-year decrease of 31.62%, accounting for 47.92% of the company's main business revenue [4] - The revenue breakdown for Huaxi Biological's brands includes 923 million yuan for Runbaiyan, 649 million yuan for Kuaidi, 290 million yuan for Mibeier, and 279 million yuan for BM Jihuo, indicating the absence of any 1 billion-level skincare brands [4]

科创50指数样本调整名单显示，华熙生物被调出名单。 在2024年年报中，华熙生物表示，公司已将"个人健康消费品事业线"更名为"皮肤科学创新转化事 业线"，这一年，其皮肤科学创新转化业务实现收入25.69亿元，同比下降31.62%，占公司主营业务收入 的比例进一步降至47.92%。分品牌来看，润百颜、夸迪、米蓓尔、BM肌活的营收分别为9.23亿元、 6.49亿元、2.9亿元和2.79亿元，已无10亿级护肤品牌。 （责任编辑：华青剑） | 调出名单 | | 调入名单 | | | --- | --- | --- | --- | | 证券代码 | 证券名称 | 证券代码 | 证券名称 | | 688363 | 华壁生物 | 688220 | 翱捷科技 | | 688563 | 航材股份 | 688702 | 盛科通信 | 新京报11月28日发布标题为《华熙生物旗下又一护肤品牌店铺清空，皮肤科学创新转化业务遇瓶 颈》的文章。文章称，皮肤科学创新转化业务"失速"，去年已无10亿级护肤品牌。华熙生物的调整早有 苗头。在今年半年报中，该公司指出，2024年是华熙生物组织变革元年，2025年继续推进变革。今年3 月，公司董事长 ...

Core Viewpoint - Huaxi Biological is facing a trust crisis in the capital market due to continuous shareholding reduction by original shareholders and a significant drop in stock price, which has fallen over 80% from its peak. The company's core skincare business has seen a substantial decline in revenue over the past two years, leading to a notable decrease in both revenue and net profit for the first three quarters of 2025. The company is undergoing a "bone-scraping" reform to improve profitability through cost reduction and efficiency enhancement, while also seeking new growth through external investments. However, the lack of internal growth drivers and the underperformance of core business pose significant challenges for the company's recovery and investment transformation [2][3][4]. Financial Performance - As of November 6, 2025, Huaxi Biological's stock price was 49.8 yuan per share, representing an over 82% decline from its historical peak, with a market capitalization of only 24 billion yuan, down more than 120 billion yuan from its peak [4]. - For the first three quarters of 2025, the company reported revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% compared to the previous year [4][5]. - The core skincare innovation business has seen a continuous decline in revenue, with a drop of 8.5 billion yuan in 2023 and a further decline to 2.569 billion yuan in 2025, reflecting a year-on-year decrease of over 30% [5][6]. Business Challenges - The raw materials and medical terminal segments have also experienced declines, with the raw materials business showing a slight decrease of 0.58% in the first half of 2025, and the medical terminal business declining by 9.44% [6]. - The company's cost control measures have led to a reduction in sales expenses, which decreased by 5.14 billion yuan to 1.117 billion yuan in the first three quarters of 2025, resulting in a sales expense ratio of 34.26%, down 31.50% [9][10]. Strategic Initiatives - The company has initiated a brand "slimming" plan, shutting down non-core brands to focus on its main business. It has also made significant external investments, totaling 1.009 billion yuan across seven private equity funds, although these investments have not yet yielded substantial returns [10][11]. - Huaxi Biological has made strategic investments in biotechnology and pharmaceuticals, including a 138 million HKD investment in a Hong Kong-based company, aiming to enhance its platform value in the synthetic biology era [11]. Future Outlook - The company’s ability to recover its core skincare business and convert new investments into actual revenue will be critical for regaining trust in the capital market. The current profit improvements are seen as temporary measures, and without a return to double-digit revenue growth, the company may face further challenges in maintaining profitability [10][12].

Core Viewpoint - The article discusses the strategic transformation of the brand Quadi, emphasizing its emotional connection with consumers and the introduction of the CT50 patented technology for anti-aging skincare, which is positioned as a "cell charger" for skin health [2][12][38]. Group 1: Brand Transformation - Quadi has appointed Yang Tianzhen as its brand energy ambassador, launching the slogan "Use Quadi to Avoid Collapse," which resonates emotionally with consumers sharing their personal stories of resilience [2][4]. - The brand has undergone a comprehensive renewal over the past year, focusing on brand value propositions, scientific positioning, and narrative development [4][12]. - Quadi's brand narrative has evolved to emphasize "energy skincare," aligning with consumer preferences for scientific and effective skincare solutions [27][34]. Group 2: Market Challenges - Huaxi Biological, Quadi's parent company, has faced challenges in the efficacy skincare market despite high R&D investment, with R&D expenses rising from 6.15% in 2020 to 10.22% by mid-2025, totaling 1.977 billion yuan over five years [6][9]. - Consumer behavior has shifted, with over 80% prioritizing "ingredients and efficacy" over "brand recognition," necessitating clear differentiation in market positioning [9][12]. Group 3: CT50 Technology - The CT50 technology, developed from Huaxi Biological's acquisition of RevitaCare Lab, focuses on non-crosslinked hyaluronic acid and aims to create a favorable environment for cell health [20][22]. - CT50 combines various active ingredients into three functional packages: cell nutrition support, signal enhancement, and mitochondrial energy remodeling, forming a comprehensive "cell charging solution" [25][26]. - The technology is positioned as a key competitive advantage for Quadi, leveraging Huaxi Biological's extensive research capabilities and infrastructure [26][38]. Group 4: Brand Narrative Framework - Quadi's new narrative framework consists of four dimensions: personal growth, technological innovation, women's empowerment, and authentic user experiences, enhancing consumer engagement [27][28]. - The brand's archetype has shifted from "Caregiver" to include "Hero," reflecting a strategic upgrade to position itself as a solution provider against aging and stress [34][35]. - This transformation aims to establish Quadi as a "cell anti-aging expert" in consumers' minds, aligning with the industry's trend towards science-driven branding [38][41].

Core Insights - The 2025 High-Quality Development Forum for Listed Companies and the 27th Golden Bull Award Ceremony took place in Nantong, Jiangsu, highlighting the theme "Moving Towards New Horizons for a Sustainable Future" [1] - Huaxi Biological, established in 2000, is recognized as a global leader in biotechnology and biomanufacturing, focusing on innovative solutions in aging intervention and tissue regeneration [1] - The Golden Bull Award, initiated in 1999 by China Securities Journal, aims to create a transparent and credible platform for recognizing outstanding listed companies in China's capital market [1] Company Overview - Huaxi Biological has built the world's largest synthetic biological manufacturing platform, offering integrated solutions across pharmaceuticals, medical aesthetics, nutritional science, and dermatology [1] - The company has developed several brands, including Runbaiyan, Kuaidi, Mibeier, Jihuo, and Huaxi Dangkang, showcasing its diverse product offerings [1] Award Details - The Golden Bull Award includes nine categories, such as "Most Investment Value Award," "Golden Bull Outstanding Entrepreneur Award," and "Golden Bull Secretary Award," recognizing excellence in corporate governance and investor relations [2] - The "Golden Bull Secretary Award" specifically honors company secretaries who excel in governance, equity management, information disclosure, and investor relations [2]

Core Viewpoint - The article discusses the challenges faced by Huaxi Biological, particularly its declining performance and the strategic changes initiated by its founder Zhao Yan to revitalize the company after a period of poor financial results [5][19]. Financial Performance - In the first three quarters of 2025, Huaxi Biological reported revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [5]. - The decline in profit is attributed to the drop in revenue from the skin science innovation transformation business, previously known as functional skincare products [5][10]. - Despite the overall decline, there was a notable improvement in the second quarter of 2024, with net profit increasing by 20.89% year-on-year, marking the first growth since the second quarter of 2024 [5][6]. Strategic Changes - Zhao Yan returned to the operational front line in March 2024, initiating a comprehensive reform of the company's management, sales expenses, and strategic direction [5][19]. - The company has reduced its sales expense ratio to 34.26%, the lowest in five years, by cutting costs in marketing and promotional activities [6]. - Huaxi Biological is undergoing a transformation process that includes organizational restructuring, talent system adjustments, and marketing model innovations [7][19]. Market Context - The medical beauty market is rapidly changing, with Huaxi Biological's market value dropping significantly from nearly 150 billion yuan at its peak in July 2021 to 25.977 billion yuan by October 29, 2024 [9]. - The stock price has also seen a dramatic decline, falling over 82% from its historical high of 312.99 yuan per share [9][10]. - The emergence of collagen peptide products has shifted investor focus away from hyaluronic acid, leading to a decline in Huaxi Biological's market position [12][13]. Competitive Landscape - Other companies in the hyaluronic acid sector, such as Haohai Biological and Aimeike, have also experienced significant stock price declines, indicating a broader trend in the market [11]. - New entrants focusing on collagen products have gained traction, with companies like Juzhibio and Jinbo Biological reporting substantial revenue growth, further challenging Huaxi Biological's market share [12][13]. Product Performance - The functional skincare product line, once a growth driver, has seen revenue declines exceeding 15% year-on-year in recent quarters, significantly impacting overall performance [6][13]. - The revenue from key brands like Runbaiyan and Kuaidi has also decreased, with projections indicating further declines in 2024 [21].

Core Viewpoint - The return of Zhao Yan, the founder of Hyaluronic Acid Biotech, to the frontline of operations has not yet led to a recovery in the company's performance, which remains in decline despite some signs of improvement in recent quarters [1][3]. Financial Performance - In the first three quarters of 2025, the company reported revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [1]. - The decline in profit is attributed to a decrease in revenue from the skin science innovation transformation business, previously known as functional skincare products [1]. - The company experienced its worst performance since its IPO in 2024, prompting Zhao Yan to return to operational management and initiate significant internal reforms [1][3]. - Despite the overall decline, the second quarter of 2025 saw a net profit increase of 20.89% year-on-year, marking the first growth since the second quarter of 2024 [1][2]. Cost Control Measures - The improvement in profit margins is primarily due to cost control, with the sales expense ratio dropping to 34.26% in the third quarter, the lowest in five years [2]. - The company has shifted away from a purely promotional sales model, focusing instead on optimizing brand research and communication, which has allowed for a significant reduction in promotional expenses [2]. Market Position and Stock Performance - The company's market capitalization has significantly decreased from nearly 150 billion yuan at its peak in July 2021 to approximately 25.977 billion yuan as of October 29, 2025, representing less than 20% of its peak value [3]. - The stock price has fallen over 82% from its all-time high of 312.99 yuan per share [3]. Industry Context - The decline in Hyaluronic Acid Biotech's performance is mirrored by other major players in the hyaluronic acid market, such as Haohai Biological and Aimeike, which have also seen significant stock price drops [5]. - The emergence of collagen peptide products has shifted investor focus away from hyaluronic acid, with companies like Juzhibio and Jinbo Biological experiencing substantial revenue growth [5][6]. - The functional skincare segment, which previously saw rapid growth, has faced challenges, with revenue declining over 15% year-on-year in both the second and third quarters of 2025 [2][6]. Strategic Adjustments - The company is undergoing a comprehensive transformation involving organizational structure, talent systems, marketing models, and supply chain collaboration [2]. - Zhao Yan's return to the operational front is seen as a critical move to address the company's recent performance issues and align its strategies with market changes [9][10].

Core Insights - The rise of new consumer brands in Jinan is driven by technological advancements and a focus on meeting consumer needs, showcasing the potential of local industries to innovate and adapt [2][3][4][5][6][7] Group 1: Technological Innovation - Tanghe Tang Biotechnology, a subsidiary of Shengquan Group, has transformed from a traditional industrial player to a high-end food ingredient provider, increasing its revenue from 10 million to over 400 million yuan through the development of a fully automated xylitol production line [3] - Huaxi Biological has shifted from B2B to B2C, investing 3 billion yuan to build the world's largest pilot platform, enabling rapid transformation of research into consumer products and achieving a 44% global market share in hyaluronic acid [4] - The technological breakthroughs in these companies have restructured the supply chain and allowed Jinan's manufacturing sector to penetrate the functional sugar market, with Tanghe Tang aiming for an annual output value of 1 billion yuan in the next 3-5 years [3][4] Group 2: Market Demand and Consumer Focus - Tangpai Group has been addressing the silver economy since 2010, creating a comprehensive supply chain for elderly products, with over 3,000 items integrated into its brand, and establishing the first silver economy center in Shandong [6] - The company has introduced a new consumption model that includes a silver economy center, elderly care display center, and community service stations, ensuring accessibility and affordability of products for the elderly [6] - Weirkan Group has transformed from a traditional meat processing factory to a cold chain service provider, expanding its cold storage capacity from 10,000 tons to 360,000 tons and increasing its distributor network from 200 to over 1,800 [7]

Core Insights - A new wave of consumer brands is emerging in Jinan, focusing on various sectors such as beauty, silver economy products, functional sugars, and cold chain food, driven by technological advancements and market demand [2][5]. Group 1: Company Developments - Huaxi Biological has transitioned from a B2B model supplying hyaluronic acid to a B2C model, investing 3 billion yuan to build the world's largest pilot platform, enhancing its product development capabilities and market responsiveness [4]. - Tanghe Tang Biotechnology, a subsidiary of Shengquan Group, has evolved from a 10 million yuan revenue company in 2008 to over 400 million yuan by leveraging patented technology to produce high-value functional sugars [3]. - Tangpai Group has established a comprehensive supply chain for silver economy products, offering over 3,000 types of products and creating a new consumption model with a focus on elderly care [5]. Group 2: Market Trends - The silver economy is gaining traction in China, with Tangpai Group addressing the supply-demand mismatch by launching 20-30 new products weekly domestically and 100-200 products internationally [5]. - The cold chain logistics sector is being transformed by Weierkang Group, which has expanded its cold storage capacity from 10,000 tons to 360,000 tons, establishing a nationwide distribution network [6][7].